Funding for this research was provided by:
Division of Diabetes, Endocrinology, and Metabolic Diseases (F32DK127545)
Article History
Received: 16 June 2023
Accepted: 31 July 2023
First Online: 16 September 2023
Acknowledgements
: This manuscript was prepared using Action to Control Cardiovascular Risk in Diabetes (ACCORD) data obtained from the NHLBI BioLINCC and does not necessarily reflect the opinions or views of ACCORD or the NHLBI.
: The data that support the findings of this study are not openly available for reasons of sensitivity but may be accessed from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC; ExternalRef removed) pending institutional review board and repository approval.
: SJC was supported by the National Institutes of Health (grant no. F32DK127545) and the American Diabetes Association (grant no. 7–21-JDFM-005). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
: SJC reports a close family member employed by a Johnson & Johnson company and has served on advisory boards for Alexion Pharmaceuticals. DJW reports serving on the Data Monitoring Committees for Novo Nordisk. TT declares that there are no relationships or activities that might bias, or be perceived to bias, their work.
: The study was conceived by SJC and DJW. The analysis was performed by SJC and TT. All authors contributed substantially to the design and interpretation of the study, critically reviewed the manuscript and provided final approval for publication. SJC is the guarantor of this work.
Free to read: This content has been made available to all.